Alpha Tau price target raised to $9 from $7 at Citi
Citi analyst Yigal Nochomovitz raised the firm’s price target on Alpha Tau (DRTS) to $9 from $7 and keeps a Buy rating on the shares. The firm believes the company’s radiopharma platform is being underappreciated at current share levels. Alpha Tau’s “broader-than-expected” Japan approval in head and neck cancer is leading to partnership opportunities, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
See the top stocks recommended by analysts >>
Read More on DRTS:
- Alpha Tau Medical: U.S. Trial Expansion, Japan Approval, and Manufacturing Scale-Up Support Buy Rating Despite Near-Term Losses
- Alpha Tau Posts Wider 2025 Loss as Japanese Approval and U.S. Trial Progress Mark Pivotal Year
- Alpha Tau downgraded to Neutral from Overweight at Piper Sandler
- DRTS Earnings this Week: How Will it Perform?
- Alpha Tau Lands First International Approval as Japan Grants Marketing Clearance for Alpha DaRT (NASDAQ: DRTS)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
3 Altcoins to Watch in the First Week of November 2026
Trump and Jim Cramer Defend SpaceX as Musk Wants to Enter the Telecom Market
Gold’s lost haven allure to swing back into view on deficit woes
Crypto prices
More
